Published in AIDS on October 18, 2007
Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. J Immunol (2010) 1.42
Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology (2009) 1.02
Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood (2012) 0.98
Mucosal immunity to HIV: a review of recent literature. Curr Opin HIV AIDS (2008) 0.89
A novel population of human CD56+ human leucocyte antigen D-related (HLA-DR+) colonic lamina propria cells is associated with inflammation in ulcerative colitis. Clin Exp Immunol (2009) 0.81
Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac₂₅₁ infection of macaques. Virology (2014) 0.79
Advances in sexually transmitted infections of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2009) 0.77
Higher Frequency of NK and CD4+ T-Cells in Mucosa and Potent Cytotoxic Response in HIV Controllers. PLoS One (2015) 0.75
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS (2002) 4.42
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Genome sequence of an Australian kangaroo, Macropus eugenii, provides insight into the evolution of mammalian reproduction and development. Genome Biol (2011) 2.18
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis (2005) 2.07
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol (2007) 1.96
When should antiretroviral therapy for HIV be started? BMJ (2007) 1.95
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med (2006) 1.65
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection. Blood (2012) 1.60
Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr (2005) 1.50
Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther (2005) 1.48
Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis (2010) 1.43
The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml. AIDS (2002) 1.41
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS (2002) 1.40
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS (2013) 1.28
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS (2004) 1.26
Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS (2005) 1.18
Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes. Diabetes (2006) 1.10
Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers. PLoS One (2009) 1.06
Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients. AIDS (2007) 0.99
No change to HIV-1 latency with valproate therapy. AIDS (2006) 0.98
Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? AIDS (2002) 0.98
Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens. Immunology (2014) 0.96
Evolution of coding and non-coding genes in HOX clusters of a marsupial. BMC Genomics (2012) 0.95
Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010. PLoS One (2012) 0.94
HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation. Antivir Ther (2007) 0.94
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr (2005) 0.93
Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individuals. AIDS (2009) 0.91
Reduced T(H)1/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection. J Allergy Clin Immunol (2011) 0.91
Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS (2002) 0.90
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr (2009) 0.89
Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. AIDS (2003) 0.89
Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis. AIDS (2002) 0.88
Successful treatment of acute haemorrhagic cytomegalovirus colitis with ganciclovir in an individual without overt immunocompromise. Eur J Gastroenterol Hepatol (2003) 0.87
Defects in the adherens junction complex (E-cadherin/ β-catenin) in inflammatory bowel disease. Cell Tissue Res (2014) 0.86
A survey of the teaching and assessment of undergraduate psychiatry in the medical schools of the United Kingdom and Ireland. Med Teach (2009) 0.85
The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir Ther (2005) 0.85
The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens. PLoS One (2009) 0.84
The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy. Clin Infect Dis (2011) 0.83
PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. Viral Immunol (2012) 0.83
The contribution of cytomegalovirus to changes in NK cell receptor expression in HIV-1-infected individuals. J Infect Dis (2007) 0.82
Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men. Br J Nutr (2009) 0.81
Killing of Kaposi's sarcoma-associated herpesvirus-infected fibroblasts during latent infection by activated natural killer cells. Eur J Immunol (2011) 0.80
The T-Cell Immune Response against Kaposi's Sarcoma-Associated Herpesvirus. Adv Virol (2011) 0.80
Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. Value Health (2009) 0.80
Enhancing genome assemblies by integrating non-sequence based data. BMC Proc (2011) 0.80
True gynaecomastia, another manifestation of immune reconstitution disease? Int J STD AIDS (2002) 0.79
Anti-TNF-Alpha-Induced Psoriasis - An Unusual Paradox. Case Rep Gastroenterol (2009) 0.79
Feature selection and classifier performance on diverse bio- logical datasets. BMC Bioinformatics (2014) 0.79
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. J Interferon Cytokine Res (2008) 0.79
Surgery in young adults with inflammatory bowel disease: a narrative account. Int J Nurs Stud (2013) 0.79
Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses. AIDS (2004) 0.78
The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood (2006) 0.78
Short communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV type 1+ individuals with high plasma viral load. AIDS Res Hum Retroviruses (2012) 0.78
Opportunistic protozoan diarrhoea. J HIV Ther (2002) 0.76
Improving HIV-specific immune responses in HIV-infected patients. J HIV Ther (2002) 0.76
ILP-based maximum likelihood genome scaffolding. BMC Bioinformatics (2014) 0.75
Ex-vivo recognition of late-lytic CD8 epitopes specific for Kaposi's sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals. Viral Immunol (2011) 0.75
CCR2/64I mutation detection in a HIV-1-positive patient with slow CD4 T-cell decline and delay in disease progression. Int J STD AIDS (2005) 0.75
Rising rates of HIV infection. BMJ (2005) 0.75
Controversies in current treatment guidelines. J HIV Ther (2008) 0.75
Coyote (Canis latrans) and domestic dog (Canis familiaris) mortality and morbidity due to a Karenia brevis red tide in the Gulf of Mexico. J Wildl Dis (2013) 0.75
Clinical utility of resistance testing. J HIV Ther (2002) 0.75
The efficacy of lopinavir in individuals experiencing protease inhibitor failure. J Acquir Immune Defic Syndr (2003) 0.75
A case of march fracture in a patient with osteoporosis on long-term HAART. Int J STD AIDS (2002) 0.75